Akorn-Strides JV submits first ANDA

 According to an official release issued today, the proposed drug is a parenteral injectable supporting the antiemetic market, which has annual sales of nearly $600 million. Patent protection for the reference-listed drug expires in September 2008.

 Arun Kumar, executive vice chairman and MD of Strides Arcolab, said: "The first ANDA filing is an important milestone for the Akorn-Strides joint venture, which further strengthens the partnership between Akorn and Strides."